Major finding: GRM3 is mutated in 16.3% of melanomas.

Impact: Screening of GPCRs identifies potential drug targets and treatment strategies.

Approach: Exon capture and massively parallel sequencing were performed on 734 GPCRs.

This content is only available via PDF.
©2011 American Association for Cancer Research.
2011